The Indian company, Eris Lifesciences, has snapped up the Zomelis trademark for vildagliptin-based formulations from Novartis AG for the Indian market, just ahead of the expiry of a key patent on the DPP-4 inhibitor.
Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
